Publication: Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
| dc.contributor.author | Ampuero, Javier | |
| dc.contributor.author | Gallego-Duran, Rocio | |
| dc.contributor.author | Romero-Gomez, Manuel | |
| dc.date.accessioned | 2023-02-09T10:38:40Z | |
| dc.date.available | 2023-02-09T10:38:40Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Mao et al. suggest the modification of several parameters employed in the paper for the diagnosis of the dysmetabolic-related outcomes. First, these authors propose using glucose intolerance tests instead of a diagnosis of type 2 diabetes mellitus as an outcome measure . We fully agree with the correspondents about the usefulness of the early detection of glucose intolerance due to the capacity to prevent further events in patients at risk of progressing to diabetes mellitus . However, these tests, such as oral glucose tolerance test , are not suitable for a wide screening of patients because they are time -consuming (2 hours duration) and not cost -effective in this scenario.3 Further, these tests are typically carried out in dedicated units, such as Endocrinology units | |
| dc.description.version | Si | |
| dc.identifier.citation | Ampuero J, Gallego-Durán R, Romero-Gómez M. Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". J Hepatol. 2021 Apr;74(4):971-972. | |
| dc.identifier.doi | 10.1016/j.jhep.2020.12.020 | |
| dc.identifier.essn | 1600-0641 | |
| dc.identifier.pmid | 33359898 | |
| dc.identifier.unpaywallURL | http://www.journal-of-hepatology.eu/article/S0168827820338952/pdf | |
| dc.identifier.uri | http://hdl.handle.net/10668/16846 | |
| dc.issue.number | 4 | |
| dc.journal.title | Journal of hepatology | |
| dc.journal.titleabbreviation | J Hepatol | |
| dc.language.iso | en | |
| dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
| dc.organization | Hospital Universitario Virgen del Rocío | |
| dc.page.number | 971-972 | |
| dc.publisher | Elsevier BV | |
| dc.pubmedtype | Letter | |
| dc.pubmedtype | Research Support, Non-U.S. Gov't | |
| dc.pubmedtype | Comment | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0168-8278(20)33895-2 | |
| dc.rights.accessRights | Restricted Access | |
| dc.subject | Fibrosis | |
| dc.subject | Humans | |
| dc.subject | Liver Cirrhosis | |
| dc.subject | Non-alcoholic Fatty Liver Disease | |
| dc.subject.decs | Intolerancia a la glucosa | |
| dc.subject.decs | Diabetes Mellitus | |
| dc.subject.decs | Prueba de Tolerancia a la glucosa | |
| dc.subject.decs | Monoaminooxidasa | |
| dc.subject.decs | Endocrinología | |
| dc.subject.mesh | Glucose Intolerance | |
| dc.subject.mesh | Diabetes Mellitus, Type 2 | |
| dc.subject.mesh | Glucose Tolerance Test | |
| dc.subject.mesh | Early Diagnosis | |
| dc.subject.mesh | Outcome Assessment, Health Care | |
| dc.title | Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". | |
| dc.type | letter to the editor | |
| dc.type.hasVersion | VoR | |
| dc.volume.number | 74 | |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format

